<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37338709</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-0267</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Clinical reviews in allergy &amp; immunology</Title><ISOAbbreviation>Clin Rev Allergy Immunol</ISOAbbreviation></Journal><ArticleTitle>Perspectives on Mycophenolate Mofetil in the Management of Autoimmunity.</ArticleTitle><Pagination><StartPage>86</StartPage><EndPage>100</EndPage><MedlinePgn>86-100</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12016-023-08963-3</ELocationID><Abstract><AbstractText>Before becoming a cornerstone in the treatment of numerous immune-mediated diseases, mycophenolate mofetil (MMF) was first introduced as an immunosuppressive agent in transplant immunology and later received the attention of rheumatologists and clinicians involved in the management of autoimmune diseases. MMF is now a widespread immunosuppressive drug for the treatment of several conditions, including lupus nephritis, interstitial lung disease associated with systemic sclerosis, and anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis while being efficacious also as rescue therapy in various orphan diseases, including dermatomyositis and IgA-associated nephropathy. Similarly, case reports or series support a possible use of MMF in other rare autoimmune diseases. Beyond modulating lymphocyte activation, MMF acts on other immune and non-immune cells and these effects may explain the therapeutic profile of this medication. The effects of MMF are broadly characterized by the impact on the immune system and the antiproliferative and antifibrotic changes induced. In this latter case, mechanistic data on fibroblasts may in the future allow to reevaluate the use of MMF in selected patients with inflammatory arthritis or systemic sclerosis. Attention must be paid towards the possible occurrence of adverse events, such as gastrointestinal complaints and teratogenicity, while the risk of infections and cancer related to MMF needs to be further investigated.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bhat</LastName><ForeName>Rithika</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Allergy, and Clinical Immunology, University of California, Davis, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tonutti</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Timilsina</LastName><ForeName>Suraj</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Allergy, and Clinical Immunology, University of California, Davis, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selmi</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. carlo.selmi@hunimed.eu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. carlo.selmi@hunimed.eu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gershwin</LastName><ForeName>M Eric</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Allergy, and Clinical Immunology, University of California, Davis, USA. megershwin@ucdavis.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Rev Allergy Immunol</MedlineTA><NlmUniqueID>9504368</NlmUniqueID><ISSNLinking>1080-0549</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>HU9DX48N0T</RegistryNumber><NameOfSubstance UI="D009173">Mycophenolic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009173" MajorTopicYN="N">Mycophenolic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015551" MajorTopicYN="N">Autoimmunity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012595" MajorTopicYN="Y">Scleroderma, Systemic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Mycophenolate mofetil</Keyword><Keyword MajorTopicYN="N">Mycophenolic acid</Keyword><Keyword MajorTopicYN="N">Systemic sclerosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>20</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>20</Day><Hour>11</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37338709</ArticleId><ArticleId IdType="doi">10.1007/s12016-023-08963-3</ArticleId><ArticleId IdType="pii">10.1007/s12016-023-08963-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lipsky JJ (1996) Mycophenolate mofetil. Lancet 348:1357&#x2013;1359</Citation><ArticleIdList><ArticleId IdType="pubmed">8918281</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(96)10310-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentley R (2001) Bartolomeo Gosio, 1863&#x2013;1944: an appreciation. Adv Appl Microbiol 48:229&#x2013;250</Citation><ArticleIdList><ArticleId IdType="pubmed">11677681</ArticleId><ArticleId IdType="doi">10.1016/S0065-2164(01)48005-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones EL, Epinette WW, Hackney VC, Menendez L, Frost P (1975) Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol 65:537&#x2013;542</Citation><ArticleIdList><ArticleId IdType="pubmed">1194717</ArticleId><ArticleId IdType="doi">10.1111/1523-1747.ep12610346</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez EC, Menendez L, Frost P (1979) Efficacy of mycophenolic acid for the treatment of psoriasis. J Am Acad Dermatol 1:531&#x2013;537</Citation><ArticleIdList><ArticleId IdType="pubmed">393732</ArticleId><ArticleId IdType="doi">10.1016/S0190-9622(79)80097-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Sievers TM, Rossi SJ, Ghobrial RM, Arriola E, Nishimura P, Kawano M, Holt CD (1997) Mycophenolate mofetil. Pharmacotherapy 17:1178&#x2013;1197</Citation><ArticleIdList><ArticleId IdType="pubmed">9399601</ArticleId></ArticleIdList></Reference><Reference><Citation>(1995) Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 345:1321&#x2013;1325</Citation></Reference><Reference><Citation>Sollinger HW (1995) Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 60:225&#x2013;232</Citation><ArticleIdList><ArticleId IdType="pubmed">7645033</ArticleId><ArticleId IdType="doi">10.1097/00007890-199508000-00003</ArticleId></ArticleIdList></Reference><Reference><Citation>(1996) A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 61:1029&#x2013;1037</Citation></Reference><Reference><Citation>Platz KP, Sollinger HW, Hullett DA, Eckhoff DE, Eugui EM, Allison AC (1991) RS-61443&#x2013;a new, potent immunosuppressive agent. Transplantation 51:27&#x2013;31</Citation><ArticleIdList><ArticleId IdType="pubmed">1987698</ArticleId><ArticleId IdType="doi">10.1097/00007890-199101000-00003</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullingham R, Monroe S, Nicholls A, Hale M (1996) Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 36:315&#x2013;324</Citation><ArticleIdList><ArticleId IdType="pubmed">8728345</ArticleId><ArticleId IdType="doi">10.1002/j.1552-4604.1996.tb04207.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullingham RES, Nicholls AJ, Kamm BR (1998) Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34:429&#x2013;455</Citation><ArticleIdList><ArticleId IdType="pubmed">9646007</ArticleId><ArticleId IdType="doi">10.2165/00003088-199834060-00002</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander S, Fleming DH, Mathew BS, Varughese S, Jeyaseelan V, Tamilarasi V, Jacob CK, John GT (2014) Pharmacokinetics of concentration-controlled mycophenolate mofetil in proliferative lupus nephritis: an observational cohort study. Ther Drug Monit 36:423&#x2013;432</Citation><ArticleIdList><ArticleId IdType="pubmed">25014074</ArticleId><ArticleId IdType="doi">10.1097/FTD.0000000000000031</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, Lu Y, Song G, Wang Y, Chen J, Xiao C, Zhong L, Sun X, Peng Z, Wang X (2018) In vitro study on influences of UGT1A8 gene polymorphisms on mycophenolate mofetil metabolism. Exp Clin Transplant 16:466&#x2013;472</Citation><ArticleIdList><ArticleId IdType="pubmed">29025387</ArticleId></ArticleIdList></Reference><Reference><Citation>Coskun Benlidayi I, Gokce Kutsal Y (2022) Antirheumatic drugs in older adults and polypharmacy issues. Z Gerontol Geriatr 55:507&#x2013;512</Citation><ArticleIdList><ArticleId IdType="pubmed">34114088</ArticleId><ArticleId IdType="doi">10.1007/s00391-021-01907-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Viktil KK, Enstad M, Kutschera J, Smedstad LM, Schj&#xf8;tt J (2001) Polypharmacy among patients admitted to hospital with rheumatic diseases. Pharm World Sci 23:153&#x2013;158</Citation><ArticleIdList><ArticleId IdType="pubmed">11599202</ArticleId><ArticleId IdType="doi">10.1023/A:1011909827909</ArticleId></ArticleIdList></Reference><Reference><Citation>Kees MG, Steinke T, Moritz S, Rupprecht K, Paulus EM, Kees F, Bucher M, Faerber L (2012) Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers. J Clin Pharmacol 52:1265&#x2013;1272</Citation><ArticleIdList><ArticleId IdType="pubmed">21903891</ArticleId><ArticleId IdType="doi">10.1177/0091270011412968</ArticleId></ArticleIdList></Reference><Reference><Citation>Morii M, Ueno K, Ogawa A et al (2000) Impairment of mycophenolate mofetil absorption by iron ion. Clin Pharmacol Ther 68:613&#x2013;616</Citation><ArticleIdList><ArticleId IdType="pubmed">11180021</ArticleId><ArticleId IdType="doi">10.1067/mcp.2000.111480</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanford M, Keating GM (2008) Enteric-coated mycophenolate sodium: a review of its use in the prevention of renal transplant rejection. Drugs 68:2505&#x2013;2533</Citation><ArticleIdList><ArticleId IdType="pubmed">19016576</ArticleId><ArticleId IdType="doi">10.2165/0003495-200868170-00007</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarti K, Frame D, Al Abbas M, McCune WJ (2021) The use of mycophenolate mofetil area under the curve. Curr Opin Rheumatol 33:221&#x2013;232</Citation><ArticleIdList><ArticleId IdType="pubmed">33741807</ArticleId><ArticleId IdType="doi">10.1097/BOR.0000000000000799</ArticleId></ArticleIdList></Reference><Reference><Citation>Zabotti A, Baraldo M, Quartuccio L, Sacco S, De Marchi G, De Vita S (2015) Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring. Clin Rheumatol 34:171&#x2013;174</Citation><ArticleIdList><ArticleId IdType="pubmed">25249327</ArticleId><ArticleId IdType="doi">10.1007/s10067-014-2786-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Pareek V, Pedley AM, Benkovic SJ (2021) Human de novo purine biosynthesis. Crit Rev Biochem Mol Biol 56:1&#x2013;16</Citation><ArticleIdList><ArticleId IdType="pubmed">33179964</ArticleId><ArticleId IdType="doi">10.1080/10409238.2020.1832438</ArticleId></ArticleIdList></Reference><Reference><Citation>Allison AC, Eugui EM (2000) Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47:85&#x2013;118</Citation><ArticleIdList><ArticleId IdType="pubmed">10878285</ArticleId><ArticleId IdType="doi">10.1016/S0162-3109(00)00188-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Alamilla-Sanchez ME, Alcala-Salgado MA, Alonso-Bello CD, Fonseca-Gonzalez GT (2021) Mechanism of action and efficacy of immunosupressors in lupus nephritis. Int J Nephrol Renovasc Dis 14:441&#x2013;458</Citation><ArticleIdList><ArticleId IdType="pubmed">34924767</ArticleId><ArticleId IdType="pmc">8675090</ArticleId><ArticleId IdType="doi">10.2147/IJNRD.S335371</ArticleId></ArticleIdList></Reference><Reference><Citation>Allison AC, Hovi T, Watts RW, Webster AD (1975) Immunological observations on patients with Lesch-Nyhan syndrome, and on the role of de-novo purine synthesis in lymphocyte transformation. Lancet 2:1179&#x2013;1183</Citation><ArticleIdList><ArticleId IdType="pubmed">53661</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(75)92661-6</ArticleId></ArticleIdList></Reference><Reference><Citation>De Santis M, Motta F, Isailovic N et al (2022) Dose-dependent impairment of the immune response to the moderna-1273 mRNA vaccine by mycophenolate mofetil in patients with rheumatic and autoimmune liver diseases. Vaccines (Basel) 10:801</Citation><ArticleIdList><ArticleId IdType="pubmed">35632557</ArticleId><ArticleId IdType="doi">10.3390/vaccines10050801</ArticleId></ArticleIdList></Reference><Reference><Citation>Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O&#x2019;Nan P, Roth D (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350:971&#x2013;980</Citation><ArticleIdList><ArticleId IdType="pubmed">14999109</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa031855</ArticleId></ArticleIdList></Reference><Reference><Citation>Allison A (2005) Mechanisms of action of mycophenolate mofetil. Lupus 14:2&#x2013;8</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203305LU2109OA</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicinnati VR, Hou J, Lindemann M, Horn PA, Sotiropoulos GC, Paul A, Gerken G, Beckebaum S (2009) Mycophenolic acid impedes the antigen presenting and lymph node homing capacities of human blood myeloid dendritic cells. Transplantation 88:504&#x2013;513</Citation><ArticleIdList><ArticleId IdType="pubmed">19696633</ArticleId><ArticleId IdType="doi">10.1097/TP.0b013e3181b0e608</ArticleId></ArticleIdList></Reference><Reference><Citation>Colic M, Stojic-Vukanic Z, Pavlovic B, Jandric D, Stefanoska I (2003) Mycophenolate mofetil inhibits differentiation, maturation and allostimulatory function of human monocyte-derived dendritic cells. Clin Exp Immunol 134:63&#x2013;69</Citation><ArticleIdList><ArticleId IdType="pubmed">12974756</ArticleId><ArticleId IdType="pmc">1808848</ArticleId><ArticleId IdType="doi">10.1046/j.1365-2249.2003.02269.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontova P, Rama I, Llaud&#xf3; I et al (2021) Mycophenolic acid interferes the transcriptional regulation and protein trafficking of maturation surface markers in dendritic cells. Int Immunopharmacol 91:107025</Citation><ArticleIdList><ArticleId IdType="pubmed">33360369</ArticleId><ArticleId IdType="doi">10.1016/j.intimp.2020.107025</ArticleId></ArticleIdList></Reference><Reference><Citation>Shigesaka M, Ito T, Inaba M et al (2020) Mycophenolic acid, the active form of mycophenolate mofetil, interferes with IRF7 nuclear translocation and type I IFN production by plasmacytoid dendritic cells. Arthritis Res Ther 22:264</Citation><ArticleIdList><ArticleId IdType="pubmed">33168076</ArticleId><ArticleId IdType="pmc">7654586</ArticleId><ArticleId IdType="doi">10.1186/s13075-020-02356-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonutti A, Motta F, Ceribelli A, Isailovic N, Selmi C, De Santis M (2022) Anti-MDA5 antibody linking COVID-19, type i interferon, and autoimmunity: a case report and systematic literature review. Front Immunol 13:937667</Citation><ArticleIdList><ArticleId IdType="pubmed">35833112</ArticleId><ArticleId IdType="pmc">9271786</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.937667</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Tang Q, Zhao M et al (2015) The effect of mycophenolic acid on epigenetic modifications in lupus CD4+T cells. Clin Immunol 158:67&#x2013;76</Citation><ArticleIdList><ArticleId IdType="pubmed">25791245</ArticleId><ArticleId IdType="doi">10.1016/j.clim.2015.03.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson CA, Carlsten H (2003) Mycophenolic acid inhibits inosine 5&#x2019;-monophosphate dehydrogenase and suppresses immunoglobulin and cytokine production of B cells. Int Immunopharmacol 3:31&#x2013;37</Citation><ArticleIdList><ArticleId IdType="pubmed">12538032</ArticleId><ArticleId IdType="doi">10.1016/S1567-5769(02)00210-2</ArticleId></ArticleIdList></Reference><Reference><Citation>von Borstel A, Abdulahad WH, Dekkema G, Rutgers A, Stegeman CA, Veldman J, Heeringa P, Sanders JS (2020) Mycophenolic acid and 6-mercaptopurine both inhibit B-cell proliferation in granulomatosis with polyangiitis patients, whereas only mycophenolic acid inhibits B-cell IL-6 production. PLoS ONE 15:e0235743</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0235743</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliyu M, Zohora FT, Anka AU, Ali K, Maleknia S, Saffarioun M, Azizi G (2022) Interleukin-6 cytokine: an overview of the immune regulation, immune dysregulation, and therapeutic approach. Int Immunopharmacol 111:109130</Citation><ArticleIdList><ArticleId IdType="pubmed">35969896</ArticleId><ArticleId IdType="doi">10.1016/j.intimp.2022.109130</ArticleId></ArticleIdList></Reference><Reference><Citation>Remuzzi G, Zoja C, Gagliardini E, Corna D, Abbate M, Benigni A (1999) Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J Am Soc Nephrol 10:1542&#x2013;1549</Citation><ArticleIdList><ArticleId IdType="pubmed">10405210</ArticleId><ArticleId IdType="doi">10.1681/ASN.V1071542</ArticleId></ArticleIdList></Reference><Reference><Citation>Morath C, Zeier M (2003) Review of the antiproliferative properties of mycophenolate mofetil in non-immune cells. Int J Clin Pharmacol Ther 41:465&#x2013;469</Citation><ArticleIdList><ArticleId IdType="pubmed">14703952</ArticleId><ArticleId IdType="doi">10.5414/CPP41465</ArticleId></ArticleIdList></Reference><Reference><Citation>Morath C, Schwenger V, Beimler J, Mehrabi A, Schmidt J, Zeier M, Muranyi W (2006) Antifibrotic actions of mycophenolic acid. Clin Transplant 20(Suppl 17):25&#x2013;29</Citation><ArticleIdList><ArticleId IdType="pubmed">17100698</ArticleId><ArticleId IdType="doi">10.1111/j.1399-0012.2006.00597.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Morath C, Reuter H, Simon V et al (2008) Effects of mycophenolic acid on human fibroblast proliferation, migration and adhesion in vitro and in vivo. Am J Transplant 8:1786&#x2013;1797</Citation><ArticleIdList><ArticleId IdType="pubmed">18786225</ArticleId><ArticleId IdType="doi">10.1111/j.1600-6143.2008.02322.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z, Zhang L, Zhu H et al (2021) Nanoparticle formulation of mycophenolate mofetil achieves enhanced efficacy against hepatocellular carcinoma by targeting tumour-associated fibroblast. J Cell Mol Med 25:3511&#x2013;3523</Citation><ArticleIdList><ArticleId IdType="pubmed">33713546</ArticleId><ArticleId IdType="pmc">8034467</ArticleId><ArticleId IdType="doi">10.1111/jcmm.16434</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozgen M, Koca SS, Dagli AF, Gundogdu B, Ustundag B, Isik A (2012) Mycophenolate mofetil and daclizumab targeting T lymphocytes in bleomycin-induced experimental scleroderma. Clin Exp Dermatol 37:48&#x2013;54</Citation><ArticleIdList><ArticleId IdType="pubmed">22182434</ArticleId><ArticleId IdType="doi">10.1111/j.1365-2230.2011.04201.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Badid C, Vincent M, McGregor B, Melin M, Hadj-Aissa A, Veysseyre C, Hartmann DJ, Desmouliere A, Laville M (2000) Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 58:51&#x2013;61</Citation><ArticleIdList><ArticleId IdType="pubmed">10886549</ArticleId><ArticleId IdType="doi">10.1046/j.1523-1755.2000.00140.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Yung S, Zhang Q, Chau MKM, Chan TM (2015) Distinct effects of mycophenolate mofetil and cyclophosphamide on renal fibrosis in NZBWF1/J mice. Autoimmunity 48:471&#x2013;487</Citation><ArticleIdList><ArticleId IdType="pubmed">26099989</ArticleId><ArticleId IdType="doi">10.3109/08916934.2015.1054027</ArticleId></ArticleIdList></Reference><Reference><Citation>Yung S, Zhang Q, Zhang CZ, Chan KW, Lui SL, Chan TM (2009) Anti-DNA antibody induction of protein kinase C phosphorylation and fibronectin synthesis in human and murine lupus and the effect of mycophenolic acid. Arthritis Rheum 60:2071&#x2013;2082</Citation><ArticleIdList><ArticleId IdType="pubmed">19565476</ArticleId><ArticleId IdType="doi">10.1002/art.24573</ArticleId></ArticleIdList></Reference><Reference><Citation>Wollin L, Trinh-Minh T, Zhang Y, Distler JHW (2021) The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease. Clin Exp Rheumatol 39(Suppl 131):134&#x2013;141</Citation><ArticleIdList><ArticleId IdType="pubmed">33886452</ArticleId><ArticleId IdType="doi">10.55563/clinexprheumatol/g5mej7</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundmann-Kollmann M, Mooser G, Schraeder P, Zollner T, Kaskel P, Ochsendorf F, Boehncke WH, Kerscher M, Kaufmann R, Peter RU (2000) Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J Am Acad Dermatol 42:835&#x2013;837</Citation><ArticleIdList><ArticleId IdType="pubmed">10775866</ArticleId><ArticleId IdType="doi">10.1067/mjd.2000.104890</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiff M, Beaulieu A, Scott DL, Rashford M (2010) Mycophenolate mofetil in the treatment of adults with advanced rheumatoid arthritis: three 24-week, randomized, double-blind, placebo- or ciclosporin-controlled trials. Clin Drug Investig 30:613&#x2013;624</Citation><ArticleIdList><ArticleId IdType="pubmed">20626209</ArticleId><ArticleId IdType="doi">10.2165/11537460-000000000-00000</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe9;meth T, Nagy G, Pap T (2022) Synovial fibroblasts as potential drug targets in rheumatoid arthritis, where do we stand and where shall we go? Ann Rheum Dis 81:1055&#x2013;1064</Citation><ArticleIdList><ArticleId IdType="pubmed">35715191</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2021-222021</ArticleId></ArticleIdList></Reference><Reference><Citation>Grivas A, Grigoriou M, Malissovas N, Sentis G, Filia A, Flouda S, Katsimpri P, Verginis P, Boumpas DT (2022) Combined &#x2013; whole blood and skin fibroblasts- transcriptomic analysis in Psoriatic Arthritis reveals molecular signatures of activity, resistance and early response to treatment. Front Immunol 13:964274</Citation><ArticleIdList><ArticleId IdType="pubmed">36159832</ArticleId><ArticleId IdType="pmc">9493103</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.964274</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenzi E, Bulik M, Tabib T, Morse C, Sembrat J, Trejo Bittar H, Rojas M, Lafyatis R (2019) Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease. Ann Rheum Dis 78:1379&#x2013;1387</Citation><ArticleIdList><ArticleId IdType="pubmed">31405848</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2018-214865</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen N, Zhou X, Jin X et al (2022) MDA5 expression is associated with TGF-&#x3b2;-induced fibrosis: potential mechanism of interstitial lung disease in anti-MDA5 dermatomyositis. Rheumatology (Oxford) 62:373&#x2013;383</Citation><ArticleIdList><ArticleId IdType="pubmed">35412608</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/keac234</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiriakidou M, Ching CL (2020) Systemic lupus erythematosus. Ann Intern Med 172:ITC81&#x2013;ITC96</Citation></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Alunno A et al (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78:736&#x2013;745</Citation><ArticleIdList><ArticleId IdType="pubmed">30926722</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2019-215089</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Cheema K et al (2020) 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 79:713&#x2013;723</Citation><ArticleIdList><ArticleId IdType="pubmed">32220834</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2020-216924</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan TM, Li FK, Tang CS et al (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343:1156&#x2013;1162</Citation><ArticleIdList><ArticleId IdType="pubmed">11036121</ArticleId><ArticleId IdType="doi">10.1056/NEJM200010193431604</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong LM, Hooi LS, Lim TO et al (2005) Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology 10:504&#x2013;510</Citation><ArticleIdList><ArticleId IdType="pubmed">16221103</ArticleId><ArticleId IdType="doi">10.1111/j.1440-1797.2005.00444.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel GB, Contreras G, Dooley MA et al (2009) Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis. J Am Soc Nephrol 20:1103&#x2013;1112</Citation><ArticleIdList><ArticleId IdType="pubmed">19369404</ArticleId><ArticleId IdType="pmc">2678035</ArticleId><ArticleId IdType="doi">10.1681/ASN.2008101028</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan T-M, Tse K-C, Tang CS-O, Mok M-Y, Li F-K, Hong Kong Nephrology Study Group (2005) Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 16:1076&#x2013;1084</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2004080686</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginzler EM, Dooley MA, Aranow C et al (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219&#x2013;2228</Citation><ArticleIdList><ArticleId IdType="pubmed">16306519</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa043731</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh M, Solomons N, Lisk L, Jayne DRW (2013) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study. Am J Kidney Dis 61:710&#x2013;715</Citation><ArticleIdList><ArticleId IdType="pubmed">23375819</ArticleId><ArticleId IdType="doi">10.1053/j.ajkd.2012.11.042</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu W, Liu Z, Chen H, Tang Z, Wang Q, Shen K, Li L (2002) Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J (Engl) 115:705&#x2013;709</Citation><ArticleIdList><ArticleId IdType="pubmed">12133539</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Hu W, Xie H, Zhang H, Chen H, Zeng C, Liu Z, Li L (2007) Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide. Lupus 16:707&#x2013;712</Citation><ArticleIdList><ArticleId IdType="pubmed">17728363</ArticleId><ArticleId IdType="doi">10.1177/0961203307081340</ArticleId></ArticleIdList></Reference><Reference><Citation>Contreras G, Tozman E, Nahar N, Metz D (2005) Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 14(Suppl 1):s33&#x2013;38</Citation><ArticleIdList><ArticleId IdType="pubmed">15803929</ArticleId><ArticleId IdType="doi">10.1177/096120330501400107</ArticleId></ArticleIdList></Reference><Reference><Citation>Houssiau FA, D&#x2019;Cruz D, Sangle S et al (2010) Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 69:2083&#x2013;2089</Citation><ArticleIdList><ArticleId IdType="pubmed">20833738</ArticleId><ArticleId IdType="doi">10.1136/ard.2010.131995</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamirou F, D&#x2019;Cruz D, Sangle S et al (2016) Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis 75:526&#x2013;531</Citation><ArticleIdList><ArticleId IdType="pubmed">25757867</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2014-206897</ArticleId></ArticleIdList></Reference><Reference><Citation>Dooley MA, Jayne D, Ginzler EM et al (2011) Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365:1886&#x2013;1895</Citation><ArticleIdList><ArticleId IdType="pubmed">22087680</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1014460</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeher M, Doria A, Lan J, Aroca G, Jayne D, Boletis I, Hiepe F, Prestele H, Bernhardt P, Amoura Z (2011) Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus 20:1484&#x2013;1493</Citation><ArticleIdList><ArticleId IdType="pubmed">21976398</ArticleId><ArticleId IdType="doi">10.1177/0961203311418269</ArticleId></ArticleIdList></Reference><Reference><Citation>Ordi-Ros J, S&#xe1;ez-Comet L, P&#xe9;rez-Conesa M, Vidal X, Mitjavila F, Salom&#xf3; AC, Pedragosa JC, Ortiz-Santamaria V, Plana MM, Cort&#xe9;s-Hern&#xe1;ndez J (2017) Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. Ann Rheum Dis 76:1575&#x2013;1582</Citation><ArticleIdList><ArticleId IdType="pubmed">28450313</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2016-210882</ArticleId></ArticleIdList></Reference><Reference><Citation>Yahya F, Jasmin R, Ng CT, Cheah TE, Sockalingam S (2013) Open label randomized controlled trial assessing the efficacy of mycophenolate sodium against other conventional immunosuppressive agents in active systemic lupus erythematosus patients without renal involvement. Int J Rheum Dis 16:724&#x2013;730</Citation><ArticleIdList><ArticleId IdType="pubmed">24119227</ArticleId><ArticleId IdType="doi">10.1111/1756-185X.12179</ArticleId></ArticleIdList></Reference><Reference><Citation>Tselios K, Gladman DD, Su J, Urowitz MB (2016) Mycophenolate mofetil in nonrenal manifestations of systemic lupus erythematosus: an observational cohort study. J Rheumatol 43:552&#x2013;558</Citation><ArticleIdList><ArticleId IdType="pubmed">26773121</ArticleId><ArticleId IdType="doi">10.3899/jrheum.150779</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawazoe M, Kaneko K, Yamada Z et al (2019) Efficacy of mycophenolate mofetil in Japanese patients with systemic lupus erythematosus. Clin Rheumatol 38:1571&#x2013;1578</Citation><ArticleIdList><ArticleId IdType="pubmed">30778862</ArticleId><ArticleId IdType="doi">10.1007/s10067-019-04473-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CC (2007) Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review. Scand J Rheumatol 36:329&#x2013;337</Citation><ArticleIdList><ArticleId IdType="pubmed">17963161</ArticleId><ArticleId IdType="doi">10.1080/03009740701607042</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkmann ER, Andr&#xe9;asson K, Smith V (2022) Systemic sclerosis. Lancet S0140&#x2013;6736(22):01692</Citation></Reference><Reference><Citation>Kowal-Bielecka O, Fransen J, Avouac J et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76:1327&#x2013;1339</Citation><ArticleIdList><ArticleId IdType="pubmed">27941129</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2016-209909</ArticleId></ArticleIdList></Reference><Reference><Citation>Park R, Nevskaya T, Baron M, Pope JE (2022) Immunosuppression use in early systemic sclerosis may be increasing over time. J Scleroderma Relat Disord 7:33&#x2013;41</Citation><ArticleIdList><ArticleId IdType="pubmed">35386940</ArticleId><ArticleId IdType="doi">10.1177/23971983211000971</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkmann ER, Tashkin DP, Li N et al (2017) Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II. Arthritis Rheumatol 69:1451&#x2013;1460</Citation><ArticleIdList><ArticleId IdType="pubmed">28376288</ArticleId><ArticleId IdType="pmc">5560126</ArticleId><ArticleId IdType="doi">10.1002/art.40114</ArticleId></ArticleIdList></Reference><Reference><Citation>Tashkin DP, Roth MD, Clements PJ et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4:708&#x2013;719</Citation><ArticleIdList><ArticleId IdType="pubmed">27469583</ArticleId><ArticleId IdType="pmc">5014629</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(16)30152-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K-A, Kim BY, Choi SJ, Kim S-K, Kim S-H, Kim H-S (2020) A real-world experience of mycophenolate mofetil for systemic sclerosis: a retrospective multicenter observational study. Arch Rheumatol 35:366&#x2013;375</Citation><ArticleIdList><ArticleId IdType="pubmed">33458660</ArticleId><ArticleId IdType="pmc">7788657</ArticleId><ArticleId IdType="doi">10.46497/ArchRheumatol.2020.7771</ArticleId></ArticleIdList></Reference><Reference><Citation>Highland KB, Distler O, Kuwana M et al (2021) Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respir Med 9:96&#x2013;106</Citation><ArticleIdList><ArticleId IdType="pubmed">33412120</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(20)30330-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Lescoat A, Varga J, Matucci-Cerinic M, Khanna D (2021) New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine. Expert Opin Investig Drugs 30:635&#x2013;652</Citation><ArticleIdList><ArticleId IdType="pubmed">33909517</ArticleId><ArticleId IdType="pmc">8292968</ArticleId><ArticleId IdType="doi">10.1080/13543784.2021.1923693</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth M (2022) Scleroderma lung study III (SLS III): combining the anti-fibrotic effects of pirfenidone (PFD) with mycophenolate (MMF) for treating scleroderma-related interstitial lung disease. clinicaltrials.gov</Citation></Reference><Reference><Citation>Namas R, Tashkin DP, Furst DE et al (2018) Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo-controlled trials. Arthritis Care Res 70:439&#x2013;444</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23282</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinchcliff M, Toledo DM, Taroni JN et al (2018) Mycophenolate mofetil treatment of systemic sclerosis reduces myeloid cell numbers and attenuates the inflammatory gene signature in skin. J Invest Dermatol 138:1301&#x2013;1310</Citation><ArticleIdList><ArticleId IdType="pubmed">29391252</ArticleId><ArticleId IdType="pmc">6590516</ArticleId><ArticleId IdType="doi">10.1016/j.jid.2018.01.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinchcliff M, Huang C-C, Wood TA et al (2013) Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. J Invest Dermatol 133:1979&#x2013;1989</Citation><ArticleIdList><ArticleId IdType="pubmed">23677167</ArticleId><ArticleId IdType="pmc">3714324</ArticleId><ArticleId IdType="doi">10.1038/jid.2013.130</ArticleId></ArticleIdList></Reference><Reference><Citation>De Luca G, Campochiaro C, De Santis M et al (2020) Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis. Rheumatology 59:2523&#x2013;2533</Citation><ArticleIdList><ArticleId IdType="pubmed">31990340</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/kez658</ArticleId></ArticleIdList></Reference><Reference><Citation>Panopoulos S, Mavrogeni S, Vlachopoulos C, Sfikakis PP (2023) Cardiac magnetic resonance imaging before and after therapeutic interventions for systemic sclerosis-associated myocarditis. Rheumatology (Oxford, England) 62(4):1535&#x2013;1542. https://doi.org/10.1093/rheumatology/keac504</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac504</ArticleId><ArticleId IdType="pubmed">36083014</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L, Mammen AL, Miller FW (2021) Idiopathic inflammatory myopathies. Nat Rev Dis Primers 7:86</Citation><ArticleIdList><ArticleId IdType="pubmed">34857798</ArticleId><ArticleId IdType="doi">10.1038/s41572-021-00321-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundberg IE, de Visser M, Werth VP (2018) Classification of myositis. Nat Rev Rheumatol 14:269&#x2013;278</Citation><ArticleIdList><ArticleId IdType="pubmed">29651121</ArticleId><ArticleId IdType="doi">10.1038/nrrheum.2018.41</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellutti Enders F, Bader-Meunier B, Baildam E et al (2017) Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis 76:329&#x2013;340</Citation><ArticleIdList><ArticleId IdType="pubmed">27515057</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2016-209247</ArticleId></ArticleIdList></Reference><Reference><Citation>Varnier GC, Consolaro A, Cheng IL, Silva Riveiro A, Pilkington C, Ravelli A (2023) Experience with the use of mycophenolate mofetil in juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford, England) 62(SI2):SI163&#x2013;SI169. https://doi.org/10.1093/rheumatology/keac404</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac404</ArticleId><ArticleId IdType="pubmed">35929784</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddis CV, Aggarwal R (2018) Treatment in myositis. Nat Rev Rheumatol 14:279&#x2013;289</Citation><ArticleIdList><ArticleId IdType="pubmed">29593343</ArticleId><ArticleId IdType="doi">10.1038/nrrheum.2018.42</ArticleId></ArticleIdList></Reference><Reference><Citation>Mira-Avendano IC, Parambil JG, Yadav R, Arrossi V, Xu M, Chapman JT, Culver DA (2013) A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis. Respir Med 107:890&#x2013;896</Citation><ArticleIdList><ArticleId IdType="pubmed">23517887</ArticleId><ArticleId IdType="doi">10.1016/j.rmed.2013.02.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Majithia V, Harisdangkul V (2005) Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 44:386&#x2013;389</Citation><ArticleIdList><ArticleId IdType="pubmed">15572389</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/keh499</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisoni CN, Cuadrado MJ, Khamashta MA, Hughes GRV, D&#x2019;Cruz DP (2007) Mycophenolate mofetil treatment in resistant myositis. Rheumatology (Oxford) 46:516&#x2013;518</Citation><ArticleIdList><ArticleId IdType="pubmed">17003173</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/kel336</ArticleId></ArticleIdList></Reference><Reference><Citation>Edge JC, Outland JD, Dempsey JR, Callen JP (2006) Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 142:65&#x2013;69</Citation><ArticleIdList><ArticleId IdType="pubmed">16415388</ArticleId><ArticleId IdType="doi">10.1001/archderm.142.1.65</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair AM, Mathew J, Goel R, Chebbi P, Mathew AJ, Arvind G, Yadav B, Rebekah G, Prakash JAJ, Danda D (2021) Mycophenolate in idiopathic inflammatory myositis: outcome data of a large South Asian cohort. Clin Rheumatol 40:2805&#x2013;2819</Citation><ArticleIdList><ArticleId IdType="pubmed">33506372</ArticleId><ArticleId IdType="doi">10.1007/s10067-021-05590-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Huapaya JA, Silhan L, Pinal-Fernandez I et al (2019) Long-term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease. Chest 156:896&#x2013;906</Citation><ArticleIdList><ArticleId IdType="pubmed">31238042</ArticleId><ArticleId IdType="pmc">6945652</ArticleId><ArticleId IdType="doi">10.1016/j.chest.2019.05.023</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 Revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65:1&#x2013;11</Citation><ArticleIdList><ArticleId IdType="pubmed">23045170</ArticleId><ArticleId IdType="doi">10.1002/art.37715</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitching AR, Anders H-J, Basu N et al (2020) ANCA-associated vasculitis Nat Rev Dis Primers 6:71</Citation><ArticleIdList><ArticleId IdType="pubmed">32855422</ArticleId><ArticleId IdType="doi">10.1038/s41572-020-0204-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvador F (2020) ANCA associated vasculitis. Eur J Intern Med 74:18&#x2013;28</Citation><ArticleIdList><ArticleId IdType="pubmed">32005600</ArticleId><ArticleId IdType="doi">10.1016/j.ejim.2020.01.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Yates M, Watts RA, Bajema IM et al (2016) EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75:1583&#x2013;1594</Citation><ArticleIdList><ArticleId IdType="pubmed">27338776</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2016-209133</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung SA, Langford CA, Maz M et al (2021) 2021 American college of rheumatology/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 73:1366&#x2013;1383</Citation><ArticleIdList><ArticleId IdType="pubmed">34235894</ArticleId><ArticleId IdType="doi">10.1002/art.41773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu W, Liu C, Xie H, Chen H, Liu Z, Li L (2008) Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant 23:1307&#x2013;1312</Citation><ArticleIdList><ArticleId IdType="pubmed">18065810</ArticleId><ArticleId IdType="doi">10.1093/ndt/gfm780</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuin J, Stassen PM, Bogdan DI, Broekroelofs J, van Paassen P, Cohen Tervaert JW, Sanders J-S, Stegeman CA (2019) Mycophenolate mofetil versus cyclophosphamide for the induction of remission in nonlife-threatening relapses of antineutrophil cytoplasmic antibody-associated vasculitis: randomized, controlled trial. Clin J Am Soc Nephrol 14:1021&#x2013;1028</Citation><ArticleIdList><ArticleId IdType="pubmed">31253599</ArticleId><ArticleId IdType="pmc">6625631</ArticleId><ArticleId IdType="doi">10.2215/CJN.11801018</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones RB, Hiemstra TF, Ballarin J et al (2019) Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Ann Rheum Dis 78:399&#x2013;405</Citation><ArticleIdList><ArticleId IdType="pubmed">30612116</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2018-214245</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuzuya K, Morita T, Kumanogoh A (2020) Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody-associated vasculitis&#x2014;a meta-analysis. RMD Open 6:e001195</Citation><ArticleIdList><ArticleId IdType="pubmed">32371435</ArticleId><ArticleId IdType="pmc">7299518</ArticleId><ArticleId IdType="doi">10.1136/rmdopen-2020-001195</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiemstra TF, Walsh M, Mahr A et al (2010) Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody&#x2013;associated vasculitis: a randomized controlled trial. JAMA 304:2381&#x2013;2388</Citation><ArticleIdList><ArticleId IdType="pubmed">21060104</ArticleId><ArticleId IdType="doi">10.1001/jama.2010.1658</ArticleId></ArticleIdList></Reference><Reference><Citation>Berti A, Alsawas M, Jawaid T et al (2022) Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis. Nephrol Dial Transplant 37:2190&#x2013;2200</Citation><ArticleIdList><ArticleId IdType="pubmed">34910216</ArticleId><ArticleId IdType="doi">10.1093/ndt/gfab357</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayne DRW, Merkel PA, Schall TJ, Bekker P, ADVOCATE Study Group (2021) Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 384:599&#x2013;609</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2023386</ArticleId></ArticleIdList></Reference><Reference><Citation>Moiseev SV, Smitienko I, Bulanov N, Karovaikina E, Novikov PI (2020) Changing landscape of immunosuppression in ANCA-associated vasculitis. Ann Rheum Dis 79:e59&#x2013;e59</Citation><ArticleIdList><ArticleId IdType="pubmed">30755415</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2019-215123</ArticleId></ArticleIdList></Reference><Reference><Citation>Manns MP, Lohse AW, Vergani D (2015) Autoimmune hepatitis &#x2013; update 2015. J Hepatol 62:S100&#x2013;S111</Citation><ArticleIdList><ArticleId IdType="pubmed">25920079</ArticleId><ArticleId IdType="doi">10.1016/j.jhep.2015.03.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahebjam F, Vierling JM (2015) Autoimmune hepatitis Front Med 9:187&#x2013;219</Citation><ArticleIdList><ArticleId IdType="pubmed">25749982</ArticleId></ArticleIdList></Reference><Reference><Citation>European Association for the Study of the Liver (2015) EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol 63:971&#x2013;1004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2015.06.030</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennes EM, Oo YH, Schramm C et al (2008) Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 103:3063&#x2013;3070</Citation><ArticleIdList><ArticleId IdType="pubmed">18853972</ArticleId><ArticleId IdType="doi">10.1111/j.1572-0241.2008.02180.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D (2017) Autoimmune hepatitis: standard treatment and systematic review of alternative treatments. World J Gastroenterol 23:6030&#x2013;6048</Citation><ArticleIdList><ArticleId IdType="pubmed">28970719</ArticleId><ArticleId IdType="pmc">5597495</ArticleId><ArticleId IdType="doi">10.3748/wjg.v23.i33.6030</ArticleId></ArticleIdList></Reference><Reference><Citation>Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN (2011) Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-na&#xef;ve patients. J Hepatol 55:636&#x2013;646</Citation><ArticleIdList><ArticleId IdType="pubmed">21238519</ArticleId><ArticleId IdType="doi">10.1016/j.jhep.2010.12.032</ArticleId></ArticleIdList></Reference><Reference><Citation>Radboud University Medical Center (2022) A randomised, open-label clinical trial assessing the efficacy and safety of mycophenolate mofetil versus azathioprine for induction of remission in treatment naive autoimmune hepatitis. clinicaltrials.gov</Citation></Reference><Reference><Citation>Luppi F, Sebastiani M, Silva M, Sverzellati N, Cavazza A, Salvarani C, Manfredi A (2020) Interstitial lung disease in Sj&#xf6;gren&#x2019;s syndrome: a clinical review. Clin Exp Rheumatol 38(Suppl 126):291&#x2013;300</Citation><ArticleIdList><ArticleId IdType="pubmed">33095142</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong AW, Khor YH, Donohoe K et al (2022) Prescribing patterns and tolerability of mycophenolate and azathioprine in patients with nonidiopathic pulmonary fibrosis fibrotic interstitial lung disease. Ann Am Thorac Soc 19:863&#x2013;867</Citation><ArticleIdList><ArticleId IdType="pubmed">34898386</ArticleId><ArticleId IdType="doi">10.1513/AnnalsATS.202108-954RL</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero-Bueno F, Diaz Del Campo P, Trallero-Aragu&#xe1;s E et al (2020) Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum 50:776&#x2013;790</Citation><ArticleIdList><ArticleId IdType="pubmed">32534273</ArticleId><ArticleId IdType="doi">10.1016/j.semarthrit.2020.03.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer A, Brown KK, Du Bois RM et al (2013) Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 40:640&#x2013;646</Citation><ArticleIdList><ArticleId IdType="pubmed">23457378</ArticleId><ArticleId IdType="pmc">3676865</ArticleId><ArticleId IdType="doi">10.3899/jrheum.121043</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassone G, Sebastiani M, Vacchi C, Erre GL, Salvarani C, Manfredi A (2021) Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review. Drugs Context 10:2020&#x2013;8&#x2013;8</Citation></Reference><Reference><Citation>Morisset J, Johannson KA, Vittinghoff E et al (2017) Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis. Chest 151:619&#x2013;625</Citation><ArticleIdList><ArticleId IdType="pubmed">27816444</ArticleId><ArticleId IdType="doi">10.1016/j.chest.2016.10.029</ArticleId></ArticleIdList></Reference><Reference><Citation>Adegunsoye A, Morisset J, Newton CA et al (2021) Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis. Eur Respir J 57:2002872</Citation><ArticleIdList><ArticleId IdType="pubmed">33122338</ArticleId><ArticleId IdType="pmc">8104021</ArticleId><ArticleId IdType="doi">10.1183/13993003.02872-2020</ArticleId></ArticleIdList></Reference><Reference><Citation>Amati F, Spagnolo P, Oldham JM et al (2023) Treatable traits in interstitial lung diseases: a call to action. Lancet Respir Med S2213&#x2013;2600(23):00002&#x2013;00004</Citation></Reference><Reference><Citation>Karim MY, Abbs IC (2005) Mycophenolate mofetil in nonlupus glomerulonephropathy. Lupus 14(Suppl 1):s39&#x2013;41</Citation><ArticleIdList><ArticleId IdType="pubmed">15803930</ArticleId><ArticleId IdType="doi">10.1191/0961203305LU2116OA</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou J-H, Le W-B, Chen N et al (2017) Mycophenolate mofetil combined with prednisone versus full-dose prednisone in iga nephropathy with active proliferative lesions: a randomized controlled trial. Am J Kidney Dis 69:788&#x2013;795</Citation><ArticleIdList><ArticleId IdType="pubmed">28215945</ArticleId><ArticleId IdType="doi">10.1053/j.ajkd.2016.11.027</ArticleId></ArticleIdList></Reference><Reference><Citation>Natale P, Palmer SC, Ruospo M, Saglimbene VM, Craig JC, Vecchio M, Samuels JA, Molony DA, Schena FP, Strippoli GF (2020) Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev 3:CD003965</Citation></Reference><Reference><Citation>Baughman RP, Valeyre D, Korsten P et al (2021) ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. https://doi.org/10.1183/13993003.04079-2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.04079-2020</ArticleId><ArticleId IdType="pubmed">34140301</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin JM, Chasler J, Wand AL et al (2021) Management of cardiac sarcoidosis using mycophenolate mofetil as a steroid-sparing agent. J Card Fail 27:1348&#x2013;1358</Citation><ArticleIdList><ArticleId IdType="pubmed">34166800</ArticleId><ArticleId IdType="doi">10.1016/j.cardfail.2021.06.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Moravan M, Segal BM (2009) Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology 72:337&#x2013;340</Citation><ArticleIdList><ArticleId IdType="pubmed">19171830</ArticleId><ArticleId IdType="pmc">2677503</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000341278.26993.22</ArticleId></ArticleIdList></Reference><Reference><Citation>Baughman RP, Lower EE (2015) Treatment of sarcoidosis. Clin Rev Allergy Immunol 49:79&#x2013;92</Citation><ArticleIdList><ArticleId IdType="pubmed">25989728</ArticleId><ArticleId IdType="doi">10.1007/s12016-015-8492-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangialardi P, Harper R, Albertson TE (2022) The pharmacotherapeutics of sarcoidosis. Expert Rev Clin Pharmacol 15:51&#x2013;64</Citation><ArticleIdList><ArticleId IdType="pubmed">35057691</ArticleId><ArticleId IdType="doi">10.1080/17512433.2022.2032657</ArticleId></ArticleIdList></Reference><Reference><Citation>Papiris S, Stagaki E, Papadaki G et al (2019) Mycophenolate mofetil as an alternative treatment in sarcoidosis. Pulm Pharmacol Ther 58:101840</Citation><ArticleIdList><ArticleId IdType="pubmed">31518648</ArticleId><ArticleId IdType="doi">10.1016/j.pupt.2019.101840</ArticleId></ArticleIdList></Reference><Reference><Citation>Raglianti V, Rossi GM, Vaglio A (2021) Idiopathic retroperitoneal fibrosis: an update for nephrologists. Nephrol Dial Transplant 36:1773&#x2013;1781</Citation><ArticleIdList><ArticleId IdType="pubmed">33005943</ArticleId><ArticleId IdType="doi">10.1093/ndt/gfaa083</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheel PJ, Feeley N, Sozio SM (2011) Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series. Ann Intern Med 154:31&#x2013;36</Citation><ArticleIdList><ArticleId IdType="pubmed">21200036</ArticleId><ArticleId IdType="doi">10.7326/0003-4819-154-1-201101040-00005</ArticleId></ArticleIdList></Reference><Reference><Citation>Yunyun F, Yu P, Panpan Z et al (2019) Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial. Rheumatology (Oxford) 58:52&#x2013;60</Citation><ArticleIdList><ArticleId IdType="pubmed">30124952</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/key227</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Li R, Luo X et al (2023) Comparison of the efficacy and safety of leflunomide versus mycophenolate mofetil in treating IgG4-related disease: a retrospective cohort study. Clin Rheumatol. https://doi.org/10.1007/s10067-023-06528-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-023-06528-5</ArticleId><ArticleId IdType="pubmed">37270719</ArticleId><ArticleId IdType="pmc">10266998</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradbury CA, Pell J, Hill Q et al (2021) Mycophenolate mofetil for first-line treatment of immune thrombocytopenia. N Engl J Med 385:885&#x2013;895</Citation><ArticleIdList><ArticleId IdType="pubmed">34469646</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2100596</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotb R, Pinganaud C, Trichet C, Lambotte O, Dreyfus M, Delfraissy J-F, Tchernia G, Goujard C (2005) Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur J Haematol 75:60&#x2013;64</Citation><ArticleIdList><ArticleId IdType="pubmed">15946312</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0609.2005.00437.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathinam SR, Gonzales JA, Thundikandy R et al (2019) Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA 322:936&#x2013;945</Citation><ArticleIdList><ArticleId IdType="pubmed">31503307</ArticleId><ArticleId IdType="pmc">6737523</ArticleId><ArticleId IdType="doi">10.1001/jama.2019.12618</ArticleId></ArticleIdList></Reference><Reference><Citation>Beissert S, Werfel T, Frieling U et al (2006) A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 142:1447&#x2013;1454</Citation><ArticleIdList><ArticleId IdType="pubmed">17116835</ArticleId><ArticleId IdType="doi">10.1001/archderm.142.11.1447</ArticleId></ArticleIdList></Reference><Reference><Citation>Beissert S, Werfel T, Frieling U et al (2007) A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol 143:1536&#x2013;1542</Citation><ArticleIdList><ArticleId IdType="pubmed">18087004</ArticleId><ArticleId IdType="doi">10.1001/archderm.143.12.1536</ArticleId></ArticleIdList></Reference><Reference><Citation>Chams-Davatchi C, Esmaili N, Daneshpazhooh M et al (2007) Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 57:622&#x2013;628</Citation><ArticleIdList><ArticleId IdType="pubmed">17583373</ArticleId><ArticleId IdType="doi">10.1016/j.jaad.2007.05.024</ArticleId></ArticleIdList></Reference><Reference><Citation>Werth VP, Joly P, Mimouni D et al (2021) Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris. N Engl J Med 384:2295&#x2013;2305</Citation><ArticleIdList><ArticleId IdType="pubmed">34097368</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2028564</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Ma J, Chang H, Zhang X, Yin L (2021) Efficacy of mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorders: an update systematic review and meta -analysis. Multiple Sclerosis and Related Disorders 55:103181</Citation><ArticleIdList><ArticleId IdType="pubmed">34365314</ArticleId><ArticleId IdType="doi">10.1016/j.msard.2021.103181</ArticleId></ArticleIdList></Reference><Reference><Citation>Borhani-Haghighi A, Kardeh B, Banerjee S, Yadollahikhales G, Safari A, Sahraian MA, Shapiro L (2020) Neuro-Behcet&#x2019;s disease: an update on diagnosis, differential diagnoses, and treatment. Multiple Sclerosis and Related Disorders 39:101906</Citation><ArticleIdList><ArticleId IdType="pubmed">31887565</ArticleId><ArticleId IdType="doi">10.1016/j.msard.2019.101906</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrend M (2001) Adverse gastrointestinal effects of mycophenolate mofetil. Drug-Safety 24:645&#x2013;663</Citation><ArticleIdList><ArticleId IdType="pubmed">11522119</ArticleId><ArticleId IdType="doi">10.2165/00002018-200124090-00002</ArticleId></ArticleIdList></Reference><Reference><Citation>Omair MA, Alahmadi A, Johnson SR (2015) Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review PLoS One 10:e0124205</Citation><ArticleIdList><ArticleId IdType="pubmed">25933090</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0124205</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunnapradist S, Lentine KL, Burroughs TE, Pinsky BW, Hardinger KL, Brennan DC, Schnitzler MA (2006) Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 82:102</Citation><ArticleIdList><ArticleId IdType="pubmed">16861948</ArticleId><ArticleId IdType="doi">10.1097/01.tp.0000225760.09969.1f</ArticleId></ArticleIdList></Reference><Reference><Citation>Manger B, Hiepe F, Schneider M, Worm M, Wimmer P, Paulus E-M, Schwarting A (2015) Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune disease: a Phase III, open-label, single-arm, multicenter study. Clin Exp Gastroenterol 8:205&#x2013;213</Citation><ArticleIdList><ArticleId IdType="pubmed">26229499</ArticleId><ArticleId IdType="pmc">4516030</ArticleId><ArticleId IdType="doi">10.2147/CEG.S81922</ArticleId></ArticleIdList></Reference><Reference><Citation>Subedi A, Magder LS, Petri M (2015) Effect of mycophenolate mofetil on the white blood cell count and the frequency of infection in systemic lupus erythematosus. Rheumatol Int 35:1687&#x2013;1692</Citation><ArticleIdList><ArticleId IdType="pubmed">25836768</ArticleId><ArticleId IdType="pmc">5503140</ArticleId><ArticleId IdType="doi">10.1007/s00296-015-3265-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritter ML, Pirofski L (2009) Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transpl Infect Dis 11:290&#x2013;297</Citation><ArticleIdList><ArticleId IdType="pubmed">19497072</ArticleId><ArticleId IdType="pmc">2852585</ArticleId><ArticleId IdType="doi">10.1111/j.1399-3062.2009.00407.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong ZJ, De Meyer S, Clarysse C, Verslype C, Neyts J, De Clercq E, Yap SH (1999) Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro. J Viral Hepat 6:229&#x2013;236</Citation><ArticleIdList><ArticleId IdType="pubmed">10607235</ArticleId><ArticleId IdType="doi">10.1046/j.1365-2893.1999.00163.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawley T, Spear M, Guo J, Wu Y (2013) Inhibition of HIV replication in vitro by clinical immunosuppressants and chemotherapeutic agents. Cell Biosci 3:22</Citation><ArticleIdList><ArticleId IdType="pubmed">23672887</ArticleId><ArticleId IdType="pmc">3680316</ArticleId><ArticleId IdType="doi">10.1186/2045-3701-3-22</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Wang B, Huang S et al (2014) Immunosuppressive drugs modulate the replication of hepatitis B virus (HBV) in a hydrodynamic injection mouse model. PLoS ONE 9:e85832</Citation><ArticleIdList><ArticleId IdType="pubmed">24465734</ArticleId><ArticleId IdType="pmc">3897536</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0085832</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Ari Z, Zemel R, Tur-Kaspa R (2001) The addition of mycophenolate mofetil for suppressing hepatitis B virus replication in liver recipients who developed lamivudine resistance&#x2013;no beneficial effect. Transplantation 71:154&#x2013;156</Citation><ArticleIdList><ArticleId IdType="pubmed">11211184</ArticleId><ArticleId IdType="doi">10.1097/00007890-200101150-00026</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffer JT, Levy C, Hughes SM et al (2022) Stable HIV reservoir despite prolonged low-dose mycophenolate to limit CD4+ T-cell proliferation. Open Forum Infect Dis 9:ofac620</Citation></Reference><Reference><Citation>Wang W-H, Lai C-C, Huang Y-F, Li T-H, Tsao Y-P, Chen W-S, Chang Y-S (2022) Pneumocystis Jirovecii pneumonia in systemic lupus erythematosus: a nationwide cohort study in Taiwan. Arthritis Care Res (Hoboken) 74:1444&#x2013;1450</Citation><ArticleIdList><ArticleId IdType="pubmed">33645012</ArticleId><ArticleId IdType="doi">10.1002/acr.24584</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu H-C, Chang Y-S, Hou T-Y et al (2021) Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study. Clin Rheumatol 40:3755&#x2013;3763</Citation><ArticleIdList><ArticleId IdType="pubmed">33646447</ArticleId><ArticleId IdType="pmc">7917170</ArticleId><ArticleId IdType="doi">10.1007/s10067-021-05660-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragoulis GE, Nikiphorou E, Dey M et al (2022) 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis ard-2022&#x2013;223335</Citation></Reference><Reference><Citation>Herrero JI, Quiroga J, Sangro B, Pardo F, Rotellar F, Alvarez-Cienfuegos J, Prieto J (2004) Herpes zoster after liver transplantation: incidence, risk factors, and complications. Liver Transpl 10:1140&#x2013;1143</Citation><ArticleIdList><ArticleId IdType="pubmed">15350004</ArticleId><ArticleId IdType="doi">10.1002/lt.20219</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CC, Tse SM, Chan KL, Ho LY (2020) Prevalence and risk factors of herpes zoster infection in patients with biopsy proven lupus nephritis undergoing immunosuppressive therapies. Lupus 29:836&#x2013;844</Citation><ArticleIdList><ArticleId IdType="pubmed">32408851</ArticleId><ArticleId IdType="doi">10.1177/0961203320923739</ArticleId></ArticleIdList></Reference><Reference><Citation>Izurieta HS, Wu X, Forshee R et al (2021) Recombinant zoster vaccine (Shingrix): real-world effectiveness in the first 2 years post-licensure. Clin Infect Dis 73:941&#x2013;948</Citation><ArticleIdList><ArticleId IdType="pubmed">33580242</ArticleId><ArticleId IdType="doi">10.1093/cid/ciab125</ArticleId></ArticleIdList></Reference><Reference><Citation>Furer V, Eviatar T, Zisman D et al (2021) Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis 80:1330&#x2013;1338</Citation><ArticleIdList><ArticleId IdType="pubmed">34127481</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2021-220647</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantauskaite M, M&#xfc;ller L, Kolb T et al (2022) Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients. Am J Transplant 22:634&#x2013;639</Citation><ArticleIdList><ArticleId IdType="pubmed">34551181</ArticleId><ArticleId IdType="pmc">8653081</ArticleId><ArticleId IdType="doi">10.1111/ajt.16851</ArticleId></ArticleIdList></Reference><Reference><Citation>Connolly CM, Chiang TP-Y, Boyarsky BJ et al (2022) Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series. Ann Rheum Dis 81:293&#x2013;295</Citation><ArticleIdList><ArticleId IdType="pubmed">34556484</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2021-221252</ArticleId></ArticleIdList></Reference><Reference><Citation>Robson R, Cecka JM, Opelz G, Budde M, Sacks S (2005) Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 5:2954&#x2013;2960</Citation><ArticleIdList><ArticleId IdType="pubmed">16303010</ArticleId><ArticleId IdType="doi">10.1111/j.1600-6143.2005.01125.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaltenborn A, Schrem H (2013) Mycophenolate mofetil in liver transplantation: a review. Ann Transplant 18:685&#x2013;696</Citation><ArticleIdList><ArticleId IdType="pubmed">24346057</ArticleId><ArticleId IdType="doi">10.12659/AOT.889299</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao EX, Betz-Stablein B, Marquat L, Campbell S, Isbel N, Green AC, Plasmeijer EI (2022) Higher mycophenolate dosage is associated with an increased risk of squamous cell carcinoma in kidney transplant recipients. Transpl Immunol 75:101698</Citation><ArticleIdList><ArticleId IdType="pubmed">35988897</ArticleId><ArticleId IdType="doi">10.1016/j.trim.2022.101698</ArticleId></ArticleIdList></Reference><Reference><Citation>Lok SD, Wong AW, Khor YH, Ryerson CJ, Johannson KA, Investigators CARE-PF (2022) Malignancy risk associated with mycophenolate mofetil or azathioprine in patients with fibrotic interstitial lung disease. Chest 161:1594&#x2013;1597</Citation><ArticleIdList><ArticleId IdType="pubmed">34921905</ArticleId><ArticleId IdType="doi">10.1016/j.chest.2021.12.636</ArticleId></ArticleIdList></Reference><Reference><Citation>Coscia LA, Armenti DP, King RW, Sifontis NM, Constantinescu S, Moritz MJ (2015) Update on the Teratogenicity of Maternal Mycophenolate Mofetil. J Pediatr Genet 4:42&#x2013;55</Citation><ArticleIdList><ArticleId IdType="pubmed">27617117</ArticleId><ArticleId IdType="pmc">4944211</ArticleId><ArticleId IdType="doi">10.1055/s-0035-1556743</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoeltzenbein M, Elefant E, Vial T, Finkel-Pekarsky V, Stephens S, Clementi M, Allignol A, Weber-Schoendorfer C, Schaefer C (2012) Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A 158A:588&#x2013;596</Citation><ArticleIdList><ArticleId IdType="pubmed">22319001</ArticleId><ArticleId IdType="doi">10.1002/ajmg.a.35223</ArticleId></ArticleIdList></Reference><Reference><Citation>Birru Talabi M, Clowse MEB (2020) Antirheumatic medications in pregnancy and breastfeeding. Curr Opin Rheumatol 32:238</Citation><ArticleIdList><ArticleId IdType="pubmed">32205567</ArticleId><ArticleId IdType="doi">10.1097/BOR.0000000000000710</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;testam Skorpen C, Hoeltzenbein M, Tincani A et al (2016) The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75:795&#x2013;810</Citation><ArticleIdList><ArticleId IdType="pubmed">26888948</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2015-208840</ArticleId></ArticleIdList></Reference><Reference><Citation>Huerta A, Caballero Bermejo AF, de Villa LF, Sedano R, Ruiz-Antor&#xe1;n B, Avenda&#xf1;o-Sol&#xe1; C, Portoles P&#xe9;rez J, Sancho-L&#xf3;pez A (2021) Measurement of the passage of mycophenolic acid into breast milk in a patient with lupus nephritis. Kidney Int 100:711</Citation><ArticleIdList><ArticleId IdType="pubmed">34420668</ArticleId><ArticleId IdType="doi">10.1016/j.kint.2021.05.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Wishart DS, Feunang YD, Guo AC et al (2018) DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 46:D1074&#x2013;D1082</Citation><ArticleIdList><ArticleId IdType="pubmed">29126136</ArticleId><ArticleId IdType="doi">10.1093/nar/gkx1037</ArticleId></ArticleIdList></Reference><Reference><Citation>Hood KA, Zarembski DG (1997) Mycophenolate mofetil: a unique immunosuppressive agent. Am J Health Syst Pharm 54:285&#x2013;294</Citation><ArticleIdList><ArticleId IdType="pubmed">9028422</ArticleId><ArticleId IdType="doi">10.1093/ajhp/54.3.285</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>